Oncology

CAR-T cells attacking a cancer cell
#CAR-T #Cell therapy #Haematology #Oncology

Coalition aims to double CAR-T therapy access by 2030

CAR T Vision has launched to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR-T therapy.   By 2030, the coalition aims to double the proportion of eligible patients treated with CAR-T therapy.   As outlined in a… Read More

#News

Prostate cancer cells
#Archeus Technologies #FDA #Oncology #Phase I trial #Prostate cancer #Radiopharmaceuticals

FDA clears radiopharmaceutical for prostate cancer

The US Food and Drug Administration (FDA) has cleared Archeus Technologies’ Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule for the imaging and treatment of prostate cancer.   This clearance enables the company to initiate a Phase I clinical trial in men with metastatic castration-resistant prostate… Read More

#Cancer Research #News #Regulatory

Blood cancer
#Cell therapy #CHMP #European Commission #Haematology #Oncology #Stem cells

Stem cell therapy gets positive CHMP opinion for blood cancers

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting conditional marketing authorisation for Zemcelpro (UM171 cell therapy).  The positive opinion relates to the treatment of adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following… Read More

#News #Regulatory

Lungs
#Antibody drug conjugate (ADC) #AstraZeneca #Daiichi Sankyo #FDA #Lung cancer #Oncology

First TROP2-directed therapy approved in the US for lung cancer

Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).  It is approved in patients who have received prior EGFR-directed therapy and platinum-based chemotherapy.  The indication was approved under accelerated approval based… Read More

#News #Regulatory #Trending News

#ASCO #Cancer research #Immunotherapy #Oncology

New DDW Highlights podcast: 22 June 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the same week DDW shared expert insights from the 2025 ASCO annual meeting, there… Read More

#News

#ASCO #Cancer research #Immunotherapy #Oncology

This week in drug discovery (16-20 June) 

News round-up for 16-20 June by DDW Senior Digital Content Editor Diana Spencer. In the same week DDW shared expert insights from the 2025 ASCO annual meeting, there have been several significant developments in oncology drug discovery, including new therapy options for some difficult to treat cancers. Read More

#News

Blood cells
#Blood cancer #Clinical trials #EHA #Haematology #Oncology

Data highlights from EHA 2025

The latest new trial data presented at the 30th European Hematology Association (EHA) 2025 Congress.  Bispecific antibody for diffuse large B-cell lymphoma Genmab shared new results from the Phase Ib/II EPCORE NHL-2 trial Arm 10 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously,… Read More

#Cancer Research #News

#Combination therapy #Immunotherapy #Oncology #The Royal Marsden NHS Foundation Trust

Adding immunotherapy improves survival rates in anal cancer

Treating advanced anal cancer patients with both immunotherapy and chemotherapy improved overall survival by an average of six months, according to a study led by The Royal Marsden NHS Foundation Trust.    Patients with advanced squamous cell anal carcinoma (SCAC) are usually treated with chemotherapy.   Results… Read More

#Cancer Research #News

X-ray showing colon cancer
#Bowel cancer #Drug resistance #Oncology #Organoids #The Institute of Cancer Research

Scientists uncover mechanism behind drug resistance in bowel cancer

Scientists at The Institute of Cancer Research (ICR), London, have discovered what may cause some treatments to stop working in people living with bowel cancer.   The findings could help researchers use information about a person’s cancer to make better use of current treatments and develop more targeted… Read More

#Cancer Research #News

Cancer research
#ASCO #Cancer immunotherapy #Cancer research #Cell therapy #Oncology #Precision medicine #Therapeutics

Expert commentary from ASCO 2025

This year’s American Society of Clinical Oncology (ASCO) Annual Meeting took place at the McCormick Place Convention Center in Chicago from 30 May to 3 June 2025. DDW’s Megan Thomas collected commentary from industry experts in attendance. CCR8 therapies gain clinical significance Stephan Schann is Chief Scientific Officer at Domain… Read More

#Cancer Research #Exclusive Content

#Combination therapy #Haematology #Lymphoma #Oncology #The Institute of Cancer Research

Drug combination treats B-cell lymphoma

Research published in the journal Blood shows that the drug tazemetostat could work better when combined with another targeted drug.   For patients with follicular lymphoma, treatment can include the drug tazemetostat – but patients have varying responses, and some see their cancer… Read More

#Cancer Research #Editor's Choice #News

Patient using a mammography machine
#AstraZeneca #Breast cancer #Cancer Research UK #Gene mutation #Oncology

New approach shows promise in aggressive breast cancers

A clinical trial for early-stage breast cancer patients with BRCA gene mutations has reported 100% survival after three years.  In a Phase III trial, Cancer Research UK researchers stopped BRCA-linked breast cancers growing or coming back by giving patients olaparib tablets 48 hours after each chemotherapy dose. … Read More

#Cancer Research #News #Trending News

#Mergers and acquisitions #Oncology #Prostate cancer #Radiopharmaceuticals #RayzeBio

RayzeBio buys prostate cancer radiopharmaceutical for $1.35bn

Philochem and RayzeBio, a subsidiary of Bristol-Myers Squibb, have announced a definitive agreement under which RayzeBio will purchase the exclusive worldwide rights to prostate cancer therapeutic OncoACP3.  OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer.   The… Read More

#Business & Investment #News

Cancer cells
#Artificial intelligence (AI) #Oncology #Parse Biosciences #Single-cell analysis #Wellcome Sanger Institute

Cancer plasticity atlas will help predict drug response

The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich has announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies.   The collaboration will catalyse an ambitious future phase to… Read More

#Cancer Research #News

#BioNTech #CureVac #Immunotherapy #Mergers and acquisitions #mRNA #Oncology

BioNTech boosts mRNA expertise with CureVac acquisition

Following a definitive Purchase Agreement, BioNTech has announced its intention to acquire all of the shares of fellow German company CureVac.  With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialisation of investigational mRNA-based cancer immunotherapies.  The company’s oncology strategy focuses on two pan-tumour programmes, mRNA-based cancer… Read More

#Business & Investment #News

Leukaemia
#AstraZeneca #Blood cancer #European Commission #Leukaemia #Oncology

Fixed-duration Calquence-based regimens approved in EU

A fixed-duration regimen of AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for previously untreated chronic lymphocytic leukaemia (CLL).  The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human… Read More

#News #Regulatory